[CH2:1]([CH:5]1[S:10][C:9]2[CH:11]=[CH:12][CH:13]=[CH:14][C:8]=2[N:7]([CH2:15][C:16]([OH:18])=O)[C:6]1=[O:19])[CH2:2][CH2:3][CH3:4].[NH2:20][C:21]1[CH:22]=[C:23]2[C:27](=[CH:28][CH:29]=1)[CH2:26][C:25]1([C:33](=[O:34])[NH:32][C:31](=[O:35])[NH:30]1)[CH2:24]2.CCN(C(C)C)C(C)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CN(C=O)C>[CH2:1]([CH:5]1[S:10][C:9]2[CH:11]=[CH:12][CH:13]=[CH:14][C:8]=2[N:7]([CH2:15][C:16]([NH:20][C:21]2[CH:22]=[C:23]3[C:27](=[CH:28][CH:29]=2)[CH2:26][C:25]2([C:33](=[O:34])[NH:32][C:31](=[O:35])[NH:30]2)[CH2:24]3)=[O:18])[C:6]1=[O:19])[CH2:2][CH2:3][CH3:4]To a solution of 2-(2-butyl-3-oxo-2H-benzo[b][1,4]thiazin-4(3H)-yl)acetic acid (0.2 mmol, 56 mg), 5′-amino-1′,3′-dihydrospiro[imidazolidine-4,2′-indene]-2,5-dione (0.2 mmol, 43 mg) and DIPEA (0.6 mmol, 104.5 μl) in DMF (1 ml) was added HATU (0.2 mmol, 76 mg) and the reaction mixture was stirred at room temperature for 16 h. Purification by preparative reverse phase HPLC using 10%-99% CH3CN (0.035% TFA)/H2O (0.05% TFA) gave the title compound. LC/MS (10% to 99%): M/Z (M+H)+ (obs)=479.2; tR=3.18. H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.55 (d, 1H), 7.42 (q, 1H), 7.25-7.33 (m, 2H), 7.16 (d, 1H), 7.07-7.15 (m, 2H), 4.86 (d, 1H), 4.60 (d, 1H), 3.59 (t, 1H), 3.27-3.34 (m, 2H), 2.97-3.04 (m, 2H), 1.6 (m, 1H), 1.24-1.28 (m, 5H), 0.83 (t, 3H).
Wird geladen…